Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Increases By 178.9%

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a significant increase in short interest in March. As of March 13th, there was short interest totaling 123,788 shares, an increase of 178.9% from the February 26th total of 44,387 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 1,966,781 shares, the days-to-cover ratio is currently 0.1 days.

Analysts Set New Price Targets

A number of analysts have commented on BAYRY shares. JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. Zacks Research downgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Finally, Barclays raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY traded up $0.07 on Thursday, reaching $11.05. 366,638 shares of the company’s stock traded hands, compared to its average volume of 1,174,640. The stock has a market cap of $43.43 billion, a PE ratio of -9.95 and a beta of 0.69. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. The stock’s 50 day simple moving average is $12.43 and its two-hundred day simple moving average is $10.18. Bayer Aktiengesellschaft has a 52-week low of $5.30 and a 52-week high of $14.85.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its earnings results on Wednesday, March 4th. The company reported $0.18 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.18. The firm had revenue of $13.24 billion during the quarter, compared to analyst estimates of $13.08 billion. Bayer Aktiengesellschaft had a positive return on equity of 15.35% and a negative net margin of 8.51%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. On average, analysts forecast that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.